# Clinical Trials Data BRAF - Document 16

# Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities

## Clinical Trial: https://clinicaltrials.gov/study/NCT01758575

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients that will start palliative treatment with TKIs, mTOR inhibitors, ipilimumab, vemurafenib or EGFR inhibitors and therefore fulfill according to their attending physician all the usual criteria for receiving standard targeted therapy as monotherapy.\n2. PT-INR/PTT \\< 1.5 x ULN.\n3. Platelet count \\>/= 100 x 109/l\n\nExclusion Criteria:\n\n1. Concomitant use of anticoagulants\n2. Previous colonic surgery in the last 3 months\n3. History of inflammatory bowel disease, or other active gastrointestinal infection",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced or metastatic solid malignancy, amenable to standard treatment with targeted agents will be included from the VUmc Medical Oncology outpatient clinic.",

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with a BRAF gene mutation would likely be eligible for this clinical trial. The inclusion criteria specify that patients who are set to receive vemurafenib as part of their palliative treatment are eligible. Vemurafenib is a targeted therapy specifically used for melanomas with BRAF V600 mutations. Therefore, if the patient meets all other specified inclusion and exclusion criteria, having a BRAF mutation would make them a suitable candidate for treatment with vemurafenib within this trial. It's important to verify with the specific clinical trial site for any additional details or updates to the eligibility criteria.